Esperion

Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers
Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers
BioSpace
Merck
PCSK9 inhibitors
Amgen
Repatha
Esperion
Sanofi
Regeneron
Praluent
Flag link:
Fortunes diverge for solo drug launchers
Fortunes diverge for solo drug launchers
EP Vantage
drug launches
Intra-Cellular Therapies
Biocryst
Horizon Therapeutics
Karyopharm Therapeutics
Blueprint Medicines
Zogenix
Esperion
Epizyme
Aurinia Pharmaceuticals
Global Blood Therapeutics
Flag link:
Esperion strikes Japan deal for 'goldilocks' cholestrol drug, bags $60M cash as pandemic forces virtual US rollout
Esperion strikes Japan deal for 'goldilocks' cholestrol drug, bags $60M cash as pandemic forces virtual US rollout
Endpoints
Esperion
Nexletol
Nexlizet
Japan
cholesterol
Flag link:
Covid-19 adds a new danger to drug launches
Covid-19 adds a new danger to drug launches
EP Vantage
drug launches
pandemic
COVID-19
Esperion
Biohaven
Urogen
Flag link:
ACC: Esperion's Nexletol busts cholesterol levels regardless of statin, ezitimibe therapy
ACC: Esperion's Nexletol busts cholesterol levels regardless of statin, ezitimibe therapy
Fierce Pharma
ACC
Esperion
Nexletol
clinical trials
c-reactive protein
Flag link:
Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Fierce Pharma
FDA
migraines
cholesterol
Epizyme
tazemetostat
Esperion
bempedoic acid
teprotumumab
Horizon Therapeutics
Biohaven
rimegepant
Flag link:
Experion’s Cholesterol Drug Looks Great in Phase III, but Faces Tough Market
Experion’s Cholesterol Drug Looks Great in Phase III, but Faces Tough Market
BioSpace
Esperion
clinical trials
bempedoic acid
American College of Cardiology
cholesterol
Flag link:
ACC 2019 preview – Bayer hopes for heart failure panache
ACC 2019 preview – Bayer hopes for heart failure panache
EP Vantage
Bayer
heart failure
Amarin
Esperion
ACC
Vascepa
bempedoic acid
Flag link:
Esperion shares bounce up on an effective triplet approach to slashing LDL
Esperion shares bounce up on an effective triplet approach to slashing LDL
Endpoints
Esperion
LDL cholesterol
bempedoic acid
Zetia
Lipitor
Flag link:
If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy
If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy
Motley Fool
Esperion
bempedoic acid
cholesterol
Flag link:
Esperion beefs up late-stage cholesterol program
Esperion beefs up late-stage cholesterol program
BioPharma Dive
Esperion
bempedoic acid
Flag link:
Biogen And Four Other Biotech Stocks Worth Watching
Biogen And Four Other Biotech Stocks Worth Watching
Forbes
Biogen
Esperion
Zafgen
Clovis Oncology
Portola
Flag link:
Esperion cholesterol drug succeeds mid-stage study
Esperion cholesterol drug succeeds mid-stage study
Yahoo/Reuters
Esperion
ETC-1002
Flag link:
In Moribund Cholesterol Field, A New Drug Emerges
In Moribund Cholesterol Field, A New Drug Emerges
Forbes
ETC-1002
Pfizer
Esperion
Merck
Amgen
Sanofi
AstraZeneca
Flag link:
Pfizer's $1.3B Esperion Loss Contained a $426M Tax Win
Pfizer's $1.3B Esperion Loss Contained a $426M Tax Win
BNET Pharma
Pfizer
Esperion
Flag link: